Abstract
In clinical trials a single dose of the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine has shown a rapid antidepressant effect in patients with treatment-resistant depression and bipolar depression. The implications of glutaminergic mechanisms in depression and the rapid effect of a single dose of ketamine could open new pathways to understand the pathophysiology of depression and the development of novel rapid-acting antidepressant drugs.
MeSH terms
-
Acute Disease
-
Analgesics, Short-Acting / administration & dosage
-
Analgesics, Short-Acting / adverse effects
-
Analgesics, Short-Acting / chemistry
-
Analgesics, Short-Acting / therapeutic use
-
Anesthetics, Dissociative / administration & dosage
-
Anesthetics, Dissociative / adverse effects
-
Anesthetics, Dissociative / chemistry
-
Anesthetics, Dissociative / therapeutic use
-
Antidepressive Agents / administration & dosage
-
Antidepressive Agents / adverse effects
-
Antidepressive Agents / chemistry
-
Antidepressive Agents / therapeutic use*
-
Bipolar Disorder / drug therapy
-
Depressive Disorder / drug therapy*
-
Excitatory Amino Acid Antagonists / administration & dosage
-
Excitatory Amino Acid Antagonists / adverse effects
-
Excitatory Amino Acid Antagonists / chemistry
-
Excitatory Amino Acid Antagonists / therapeutic use*
-
Humans
-
Ketamine / administration & dosage
-
Ketamine / adverse effects
-
Ketamine / chemistry
-
Ketamine / therapeutic use*
-
Placebos
-
Psychiatric Status Rating Scales
-
Randomized Controlled Trials as Topic
-
Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors
-
Treatment Outcome
Substances
-
Analgesics, Short-Acting
-
Anesthetics, Dissociative
-
Antidepressive Agents
-
Excitatory Amino Acid Antagonists
-
Placebos
-
Receptors, N-Methyl-D-Aspartate
-
Ketamine